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Long-term Outcomes of Childhood 
Onset nephrotic Syndrome
Rebecca Hjorten, Zohra Anwar and Kimberly Jean Reidy*
Pediatrics Nephrology, Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA
There are limited studies on long-term outcomes of childhood onset nephrotic syndrome 
(NS). A majority of children with NS have steroid-sensitive nephrotic syndrome (SSNS). 
Steroid-resistant nephrotic syndrome (SRNS) is associated with a high risk of developing 
end-stage renal disease. Biomarkers and analysis of genetic mutations may provide 
new information for prognosis in SRNS. Frequently relapsing and steroid-dependent NS 
is associated with long-term complications, including dyslipidemia, cataracts, osteopo-
rosis and fractures, obesity, impaired growth, and infertility. Long-term complications of 
SSNS are likely to be under-recognized. There remain many gaps in our knowledge of 
long-term outcomes of childhood NS, and further study is indicated.
Keywords: nephrotic syndrome, children, pediatric, outcomes, genetics, focal glomerulosclerosis, 
minimal-change disease
inTRODUCTiOn
Nephrotic syndrome (NS) is characterized by proteinuria, edema, hypoalbuminemia, and hyperlipi-
demia. The seminal studies of childhood onset NS were performed in the 1970s, in the International 
Study of Kidney Disease in Children (ISKDC) (1, 2). The ISKDC studies established the most likely 
pathologic diagnoses of childhood NS, as biopsies were performed at presentation in all 127 patients. 
Overall, the most common diagnosis (n = 95/127) was minimal-change disease (MCD), which was 
present in 94% of the children with steroid-sensitive nephrotic syndrome (SSNS) (1). In steroid-
resistant nephritic syndrome (SRNS), focal glomerulosclerosis (FSGS) was the most common histo-
pathologic lesion (1). The ISKDC established that the majority of children with NS (80%) respond 
to corticosteroid treatment (1, 2). Thus, the ISKDC established the paradigm of treating all children 
presenting with NS with corticosteroids and only performing biopsies in steroid resistant patients (2).
Since the ISKDC, the majority of studies looking at outcomes classified patients by response to 
corticosteroids or other therapy and by NS relapse. The least severe course with SSNS is associated 
with few or no relapses. More complicated are those with SSNS with frequent relapses (FR = >2 
relapses over a 6-month or >3 over a 12-month period) or steroid dependence (SD = relapses dur-
ing treatment or within 2 weeks of stopping corticosteroids) (3). Some patients with initial steroid 
response develop SRNS (late non-responders) and others present with SRNS. Finally, there are 
the most severe cases of NS that are both corticosteroid and other treatment resistant. Long-term 
renal-related complications of childhood NS would include NS relapse in adulthood, hypertension, 
chronic kidney disease (CKD), and end-stage renal disease (ESRD). Long-term non-renal complica-
tions include complications of corticosteroids and other immunosuppressant medications, including 
effects on growth, bone health, fertility, and risk for malignancy. An additional consideration are 
psychosocial issues associated with NS. As with many chronic diseases, NS can represent a barrier 
to attaining educational degrees and employment and/or developing stable relationships/marriage. 
Indeed, a quality-of-life (QOL) survey of children with NS in the National Institutes of Health Focal 
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Segmental Glomerulosclerosis (NIH FSGS) clinical trial  revealed 
that children with SRNS had poor QOL scores similar to children 
on dialysis (4).
Here, we will review the current data on long-term NS out-
comes, potential new predictors of treatment and renal outcomes, 
and gaps in our knowledge that warrant further investigation.
OUTCOMeS in SRnS
It is clear that the worst outcomes occur in SRNS, with 34–64% 
progressing to ESRD within 10  years of diagnosis (5–8). The 
majority of SRNS patients are treated with second-line agents, 
such as calcineurin inhibitors and other immunosuppressant 
medications. There is a highly variable response, which may 
depend upon the population studied. For example, studies 
of calcineurin inhibitors report divergent response rates of 
between 25 and 75% in children with SRNS (9). This variability 
in response to calcineurin inhibitors likely reflects in part differ-
ences dependent on the underlying histopathology of the SRNS, 
with MCD more likely to respond than FSGS. Other factors, 
such as race or ethnicity of the population being studied, may 
also affect likelihood of response (10). In particular, African-
American and Hispanic children with FSGS have poorer out-
comes, with one study demonstrating 50% progress to ESRD 
within 3  years (11, 12). What is clear is that response to any 
therapy is a major prognostic factor (13). Abeyagunawardena 
et  al. examined 10-year outcomes of 66 children with SRNS. 
Response to therapy was associated with 90% renal survival, 
while almost 50% with failure to respond to therapy had pro-
gressed to ESRD (13). Response to second-line immunosuppres-
sant therapy and risk of progression may differ in children who 
initially respond to therapy, but then become non-responsive 
(late non-responders). Straatmann et al. demonstrated that up 
to 87% of late non-responders in a multicenter study initially 
responded to a calcineurin inhibitor (14). However, long term, 
31% of the cohort became non-responsive, and had decreased 
renal function and increased progression to ESRD compared to 
those that remained treatment responsive (14).
BiOMARKeRS TO PReDiCT  
ReSPOnSe TO THeRAPY
One of the largest areas of research has been the search for soluble 
factors that may be predictive of treatment response and may 
also serve as targets for future therapies. This interest was partly 
spurred due to studies showing that serum from patients with 
FSGS can induce proteinuria in rats and increase the glomerular 
permeability of isolated glomeruli (15). In addition, plasma-
pheresis has been able to induce remission in some patients with 
recurrent FSGS post transplant (16, 17).
One circulating factor that has been studied is the soluble 
urokinase plasminogen activator (suPAR). Wei et al. showed in a 
study that 94 children with FSGS and 70 adults and children with 
FSGS had elevated levels of suPAR when compared with healthy 
controls (18). Peng et al. then showed, in a group of 176 children 
with idiopathic NS followed for approximately 30 months, that 
suPAR levels were able to predict steroid resistance (19). However, 
these results have not been widely reproducible, questioning the 
role of suPAR to distinguish FSGS from other glomerular diseases 
(20–22). For example, Sinha et al. in a cross-sectional cohort study 
of 83 healthy pediatric controls versus 469 patients with NS, 138 
of which had SSNS, was not able to show an association of suPAR 
levels with either SSNS versus SRNS. In the same study, suPAR 
levels were not significantly associated with the diagnosis of FSGS 
(22). This study demonstrated that suPAR had an inverse correla-
tion with glomerular filtration rate, and some have proposed it 
may be a predictor of renal progression (22, 23).
Other investigators have looked to evidence of immune 
activation to predict response to immunosuppressive treat-
ment. One study of 26 children with idiopathic SSNS that were 
followed for less than a year showed a differential pattern of 
regulatory Th1 and Th2 cells in patients in remission versus in 
relapse (24). Another study of 46 children with NS demonstrated 
that T-cell glucocorticoid receptor expression was higher in 
patients with NS responsive to steroid therapy and in patients 
with MCD, when compared to patients with FSGS (25). In one 
study of 17 patients with MCD and 22 with FSGS, urinary CD80 
(present on antigen-presenting cells and podocytes) was able to 
distinguish MCD from FSGS. Another investigator determined 
that the urinary CD80 level associated with disease remission 
(26, 27). In a search for novel, yet unrecognized, markers of both 
steroid response and disease progression, investigators have used 
unbiased approaches to examine gene expression, the serum and 
urine proteome, and the metabolome (28–30). One group took 
serum from blood of 33 children with idiopathic SSNS at pres-
entation, in remission while on medication, and in remission 
once medication was stopped. Evaluating serum peptide levels 
at all time points, they identified a novel marker, apolipoprotein 
AII. The levels of apolipoprotein AII correlated with degree of 
proteinuria at presentation and decreased with remission (31).
All these studies are limited by small numbers of patients and 
most are single-center studies. Poor reproducibility has plagued 
efforts to identify biomarkers in NS (32, 33). Thus, newly available 
large cohorts of NS patients, such as Podonet (34), NEPTUNE 
(35), and Cure GN that include well-characterized pediatric 
patient populations of NS are critical for discovery and validation 
of new biomarkers.
GeneTiC FACTORS in  
PReDiCTinG OUTCOMe in nS
One of the new factors that may predict response to therapy and 
renal outcomes are genetic variants of NS. Genetic mutations are 
most likely to be identified in congenital nephrotic syndrome 
(CNS). Mutations in NPHS1, NPHS2, LAMB2, and WT-1 were 
identified in two-thirds of a largely European cohort of 89 infants 
with NS under the age of 1 (36). The overall average age of ESRD 
was 5.6 years. While the numbers were small and many outcomes 
were not known, patients with NPHS1 mutations had ESRD at an 
average age of 4.6 years, whereas those with NPHS2 mutations 
had ESRD at an average age of 7.4 years (36). It is possible these 
differences could be explained by differences in clinical course 
TABLe 1 | Long-term complications of childhood SSnS.
Complication Reported prevalence Comment
Renal Relapses in adulthood 5–40% (47, 48) Higher risk with early onset, more 
frequent relapses in childhood
Decreased GFR/ESRD <1% at 20-year follow-up (48)
Hypertension 6–46% (49, 50) Highest in FRNS with adult relapses
Immunosuppression-related Overweight/obesity 8–23% (50, 51)
Growth failure 8–16% (48, 50)
Osteoporosis 13–63% (49, 50) Highest in FRNS with adult relapses
Fractures 20% (51)
Cataracts 6–20% (49, 50) Highest in FRNS with adult relapses
Infertility Up to 75–94% (49, 51) Highest with cytotoxic therapy
Malignancy Unknown
Psychosocial Educational status and employment <10% failure to complete high school and <45% 
unemployed (51)
Single-center study
Marital status/stable relationships <40% unmarried or not in stable relationship (51) Single-center study
3
Hjorten et al. Outcomes of Childhood Nephrotic Syndrome
Frontiers in Pediatrics | www.frontiersin.org May 2016 | Volume 4 | Article 53
and management of congenital NS (e.g., nephrectomies), rather 
than the genetic basis of disease. However, it suggests that addi-
tional studies should address whether specific genetic mutations 
correlate with outcomes in early onset NS.
There are well over 40 genetic mutations associated with FSGS, 
and new mutations continue to be identified (37). A single-gene 
mutation may be identified in up to 29% of patients with SRNS 
onset prior to age 25 (38). Patients with genetic mutations are less 
likely to respond to immunosuppressant therapy and more likely 
to develop ESRD (39). One of the largest studies by Buscher et al. 
examined renal outcomes of at 10-year follow-up of 231 children 
in a European cohort with SRNS. For those presenting after 
3 months of age, 58% children with SRNS associated with genetic 
mutations had progressed to ESRD, versus 29% with SRNS and 
no genetic mutation identified (39). Recently, genetic variants in 
APOL1 were identified as risk factors for renal disease in people 
of African descent. Carrying two copies of APOL1 coding vari-
ants (G1 and G2) is a risk factor for hypertensive nephropathy, 
lupus nephropathy, FSGS, and HIV nephropathy (40). Recent 
analysis of the FSGS Clinical Trial, a NIH supported randomized 
controlled trial comparing MMF to cyclosporine in children and 
young adults (41), demonstrated that 67–72% of 94 patients of 
African descent in the study harbored two copies of the APOL1 
risk variants, and they were more likely to progress to ESRD, with 
40% reaching ESRD within approximately 8 years (42). Of note, 
APOL1 risk variants did not associate with response to therapy, 
although a small percentage responded to either therapy (41). 
Many genetic analyses, to date, have focused on largely European 
and homogeneous populations; the cohorts of NEPTUNE (35, 
43) and CureGN provide an opportunity to understand the 
contribution of gene–gene and gene-environmental interactions 
in modulating long-term outcomes.
Recently, two genes have been identified associated with treat-
ment sensitive NS. Epithelial membrane protein 2 (EMP2) was 
identified in familial SSNS (44). While only a few patients were 
identified, the majority had no renal failure after over 20 years 
of follow-up (44). Overall, one can be optimistic that, in the 
future, identification of specific genetic mutations may help guide 
therapy and provide prognostic information to families.
LOnG-TeRM COMPLiCATiOnS OF 
STeROiD-SenSiTive nePHROTiC 
SYnDROMe ARe LiKeLY  
UnDeR-ReCOGniZeD
There is increasing focus on a life-course approach to optimizing 
health outcomes, with recognition that exposures in childhood 
establish the risk for adult-onset disease (45). The vast majority 
of children will have SSNS and MCD, which is thought to have 
benign long-term outcomes. However, recent studies have sug-
gested that other conditions that were thought to be benign, such 
as congenital solitary kidneys, are associated in increased risk of 
hypertension and ESRD in adulthood (46). The increased risk 
of ESRD required more than 30 years to manifest, and thus was 
unlikely to be detected without a concerted effort to study out-
comes in these patients (46). Potential long-term complications 
of SSNS are likely to be under-recognized, as patients are often 
lost to follow-up.
OUTCOMeS in SSnS
There are a handful of studies looking at long-term outcomes 
of childhood onset SSNS (Table  1). All studies include either 
exclusively or mostly FR/SD NS patients.
RiSK OF ReLAPSe AS An ADULT
An early study by Trompeter et  al. suggested that only 5% of 
children will have persistent relapses as adults (47). However, 
several recent studies suggest that FRNS is common, and relapses 
may persist into adulthood. Esfahani et al. examined the course 
of NS of over 200 children from Iran with follow-up between 5 
and 20  years (52). Eighty-three percent experienced relapses in 
childhood and over 50% required additional immunosuppressive 
treatment, likely indicating FR/SD NS. Less than half the cohort 
sustained a remission for more than 3 years. Similarly, Ishikura 
et al. performed 10-year follow-up of a randomized controlled trial 
of cyclosporine for FR/SDNS in Japan. Fifty percent continued to 
relapse and remain on immunosuppressives in adulthood (50).
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Fakhouri et al. studied 102/117 children admitted with SSNS 
in France using mailed questionnaires or phone calls to patients 
and/or their parents or attending physicians (48). More than 40% 
of the patients relapsed in adulthood (48). Younger age of NS 
onset, second-line immunosuppressant therapy, and more severe 
disease in childhood were associated with increased risk of relapse 
in adulthood. However, relapse rate in the first 6 months of disease 
was not predictive of adult relapses. Kabuki et al. also examined 
age of presentation effects on risk of relapse in 60 patients diag-
nosed with NS before age 10 in Japan with over 10 years follow-up 
(53). The majority (51/60) patients were relapse-free over 3 years. 
Early presentation (between age 1 and 3.9 years) was associated 
with more relapses and a longer interval between onset of NS and 
long-term remission. Conversely, older onset (after age 7 years) 
was associated with less active disease at 10 years follow-up.
Skrzypczyk et al. examined outcomes of 61/118 children with 
NS in Poland using a written questionnaire (51). Over 90% were 
SSNS and only 30% FRNS. However, 77% required second-line 
immunosuppressive therapy in addition to steroids. The patients 
had particularly benign courses in that all patients achieved 
remission and had normal renal function at the age of 18. Still 
16% relapsed in adulthood, and risk of relapse as adult was associ-
ated with relapses as a child.
One of the longest follow-up studies was by Ruth et al. on 42 
children with NS from Switzerland with a median follow-up of 
22 years. Thirty-three percent of patients had relapses as adults. 
Number of relapses during childhood and adolescence and 
requirement for second-line therapy were risks for relapses in 
adulthood (54).
RenAL AnD nOn-RenAL 
COMPLiCATiOnS
Several of these studies examined long-term complications of 
immunosuppression. Ishikura et  al. identified that on 10-year 
follow-up of exclusively FR/SDNS patients, a substantial number 
had short stature (13%), osteoporosis (13%), obesity (8%), cata-
racts (6%), and hypertension (6%) (50). Fakhouri et al. obtained 
information in their SSNS patients with 40% rate of relapse in 
adulthood (48). Of them, 7% had hypertension, and 1 out of the 
102 patients had developed ESRD. The most common complica-
tions were likely long-term side effects of corticosteroids: 16% 
had short stature, 20% were overweight or obese, and 63% had 
osteoporosis.
One of the few direct assessments of long-term outcomes 
was performed by Kyrieleis et al. in 15 adult patients from the 
Netherlands with history of childhood onset FRNS who were still 
relapsing as adults (mean follow-up 24 years). Forty-six percent 
of patients had hypertension. Dual-energy X-ray absorptiometry 
identified osteoporosis in one-third of patients. Ophthalmologic 
examination identified cataracts in 3/15 (20%) of the patients. 
Six out of eight (75%) had abnormal semen examination with 
oligozoospermia, reduced sperm motility, and teratozoospermia.
The study of 61 patients with childhood NS from Poland 
by Skrzypczyk et  al. demonstrated a substantial number of 
immunosuppressant-related complications. Sixteen percent were 
hypertensive, 23% were overweight, and 4.9% obese. Almost 
20% had bone fractures and 8% had short stature (height <third 
percentile). Childlessness was more common (94%) in those 
treated with cytotoxic agents versus those not treated with 
cytotoxic agents. No increased risk of malignancy, infection, or 
cardiovascular events was detected.
Skrzypczyk et al. was one of the only studies to examine long-
term psychosocial impact of NS as a chronic disease (51). In their 
follow-up study, 60.7% patients were in a steady relationship/
married, 40.9% pursued higher education, and only 6.6% did not 
complete a high school (secondary) education. At the time of the 
study, 55.7% patients reported active employment.
Of note, none of studies that examined GFR observed a change 
(49, 51). The study with the longest follow-up (22 years) by Ruth 
et  al. identified no effects on growth, obesity, or GFR, but did 
identify an effect on fertility (54). Only 8/42 patients had children, 
and cytotoxic therapy was associated with childlessness (54).
Nephrotic syndrome leads to endothelial dysfunction in 
children (55) and engenders a risk for artherosclerosis in adults 
(56, 57). In one study of 30 patients with childhood onset SSNS, 
dysregulation of lipids, including increased total cholesterol, low-
density lipoprotein cholesterol, and homocysteine were persistent 
on follow-up at 4–15 years after completion of steroids (57).
GAPS in OUR KnOwLeDGe OF  
LOnG-TeRM OUTCOMeS OF SSnS
The majority of the above studies are retrospective chart reviews 
or utilized surveys, with the inherent biases of those types of study 
design. Virtually, all studies lack a control population, which is 
relevant for outcomes, such as obesity and hypertension, which 
may be common in the adult population. Often they represent 
a single-center experience and have small numbers. Even the 
largest studies report outcomes from countries with homogenous 
populations, with limitations in their generalizability to ethni-
cally diverse populations. Finally, the average length of follow-up 
in most studies was approximately 10  years, well short of the 
30-year follow-up required to identify effects of a solitary kidney 
on ESRD outcomes (46).
It seems possible that, as with other conditions previously 
thought to be entirely benign, SSNS may engender increased 
risk of hypertension, atherosclerosis, CKD, and ESRD in 
adulthood (Table  2). In addition, there are insufficient studies 
of patient-reported outcomes, including QOL assessments. 
There are limited data on implications of childhood NS on 
educational attainment, employment, and marital status. Better 
understanding of potential adverse consequences may allow for 
interventions targeting improvement of both patient-reported 
and psychosocial outcomes. Our lack of knowledge limits effec-
tive transition of children with NS to adult providers. Those with 
few or no relapses are likely not to follow-up or to follow-up 
rarely with a pediatric nephrologist as they approach adulthood. 
An adult nephrologist is unlikely to follow these patients, as the 
majority will not have renal impairment at entry into adulthood. 
So the major question becomes how and when to communicate 
the potential for long-term issues with adult providers. One study 
in Japan demonstrated that the majority of practitioners had no 
transition plan in place for children with SSNS (58).
TABLe 2 | Gaps in knowledge.
Gaps in knowledge Opportunities to address
Life-course effects of childhood nS Registries of childhood onset nephrotic syndrome
Are there risks of SSNS after 30 years? Are patients with childhood onset NS at higher risk of hypertension,  
CKD, and ESRD?
cNEPTUNE (pediatric cohort of incident nephrotic 
syndrome patients)
Genetic factors and biomarkers Multicenter collaborative cohorts of pediatric  
onset NSCan permeability factors or other biomarkers enable personalized approach to treatment?
Can screening for genetic mutations or APOL1 variants in childhood onset NS stratify those children at  
highest risk for hypertension and renal disease in adulthood?
Psychosocial impact and patient-reported outcomes Multicenter collaborative cohorts of pediatric  
onset NSQuality of life is significantly affected in childhood onset NS, particularly with severe disease. What is the effect on 
patient-reported outcomes? What is the long-term effect on educational status, employment and marital/stable 
relationships and are there interventions to improve outcomes?
Transition into adulthood Registries and multicenter collaborative cohorts of 
pediatric onset NS(1) When should children with NS receive counseling about potential risks in adulthood?
(2) How will adult providers be made aware of potential for complications in adults with a history  
of childhood NS?
(3) Are screenings for artherosclerosis, osteoporosis, cataracts, infertility, and/or malignancy indicated?
(4) What is the optimal transition plan for children with SSNS as they enter adulthood?
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Patient registries and follow-up of pediatric cohorts, such 
as cNEPTUNE (incident children with NS), may help provide 
answers to these questions.
COnCLUSiOn
Underlying renal pathology, genetic factors, and ethnicity likely 
modulate response to treatment and progression of ESKD. Well-
characterized and prospectively followed cohorts provide an 
exciting opportunity to improve our understanding of the ability 
of biomarkers and genetics to predict outcomes. Many of the 
long-term complications of childhood SSNS can be attributed to 
immunosuppressant therapy. Long-term effects on endothelium 
and renal function are likely understudied. Long-term studies of 
childhood onset SSNS patients, perhaps by patient registries, are 
needed to understand the true risk of the disease to adult health.
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